Guggenheim Securities' Vamil Divan breaks down Merck's stock drop
Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.
Another pleasant evening ahead for your Tuesday night
Super Bowl 59 could be the most-watched game ever, with some viewers tuning in just for the commercials. Brands are already ...